Table 2.

Univariable and multivariable analyses of the influence of clinical parameters on PFS in NSCLC patients with different sites of metastases receiving first-line ICIs monotherapy.

	Univariable analysis			Multivariable analysis†
Factors	HR	95% CI	P	HR	95% CI	P
Age (≥65 years/<65 years)	0.477	0.220–1.036	0.062
Sex (male/female)	0.544	0.216–1.369	0.196
Smoking (ever/never)	0.815	0.368–1.807	0.614
Pathology (squamous/non-squamous)	0.732	0.320–1.676	0.460
Liver metastasis (yes/no)	4.485	1.807–11.131	0.001	7.411	2.668–20.585	0.001
Bone metastasis (yes/no)	2.129	0.969–4.678	0.060	3.475	1.438–8.395	0.006
Brain metastasis (yes/no)∗	1.765	0.639–4.874	0.273

^∗Patients with brain metastasis who previously received local treatment were excluded.

^†Variables with P < 0.20 in univariable analysis were taken forward for consideration in the multivariable analysis, and multivariable analysis was conducted using the forward stepwise regression method. CI: Confidence interval; HR: Hazard ratio; ICIs: Immune checkpoint inhibitors; NSCLC: Non-small-cell lung cancer; PFS: Progression-free survival.